Not a healthcare professional? Visit our Public site
For UK Healthcare Professionals
This site may contain promotional material
Report adverse event
User logged in
(fluticasone furoate / umeclidinium / vilanterol)
Summary of product characteristics
Patient information leaflet
This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.
Request a contact
Information to support commissioners and healthcare professionals when making a Trelegy formulary application.
Learn about how to prescribe Trelegy Ellipta, including which patients Trelegy is appropriate for, dosing and administration.
At £44.50 Trelegy Ellipta costs less than prescribing licensed multiple inhaler triple therapy. Further information can be found on our Cost of COPD therapies page.
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard.
Adverse events should also be reported to GlaxoSmithKline UK on 0800 221 441.
Trelegy and Ellipta are registered trademarks of the GlaxoSmithKline group of companies
E.I. Last updated: January 2018. UK/TLY/0041/17(2)
Get in touch
To discuss our products, supply, educational events or any other information
© 2009-2017 GSK group of companies. All rights reserved. GlaxoSmithKline UK Limited Registered in England and Wales No 4310159.
Registered office: 980 Great West Road, Brentford, Middlesex, TW8 9GS, United Kingdom.
M.C. Last updated: April 2017. UK/COM/0106/15(1).
This browser is not supported and will result in the website not being optimally presented. You are recommended to use an alternate browser such as Chrome, Opera or FireFox